Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 0.73 |
| ▸ | KDR | P35968 | 5/20 | 0.71 |
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | INSR | P06213 | 1/20 | 0.64 |
| ▸ | IGF1R | P08069 | 1/20 | 0.64 |
| ▸ | MET | P08581 | 1/20 | 0.64 |
| ▸ | SRC | P12931 | 1/20 | 0.64 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL898655 | 0.89 | ALK (0.71) | ALKKDRABL1INSRIGF1R | |
| SCHEMBL1755920 | 0.87 | ALK (0.56) | ALKKDRABL1INSRIGF1R | |
| SCHEMBL898011 | 0.87 | ALK (0.82) | ALKKDRINSR | |
| SCHEMBL898513 | 0.87 | ALK (0.76) | ALKKDRABL1INSRIGF1R | |
| SCHEMBL897216 | 0.86 | ALK (0.84) | ALKKDRABL1INSRIGF1R | |
| SCHEMBL896899 | 0.85 | ALK (1.00) | ALKKDRINSR | |
| Hydrochloric Acid SCHEMBL14990947 | 0.84 | ALK (0.98) | ALKKDRINSR | |
| Hydrochloric Acid SCHEMBL30730875 | 0.84 | ALK (0.98) | ALKKDRINSR | |
| SCHEMBL897913 | 0.84 | ALK (0.79) | ALKKDR | |
| SCHEMBL897729 | 0.83 | ALK (1.00) | ALKKDRABL1INSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| EP-3613729-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-02-26 | — | — | EP | disclosed |
| EP-3613729-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-02-26 | — | — | EP | disclosed |
| EP-3345903-B1 | TETRACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2019-10-09 | — | — | EP | disclosed |
| EP-3345903-B1 | TETRACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2019-10-09 | — | — | EP | disclosed |
| EP-3345903-A1 | TETRACYCLIC COMPOUNDS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2018-07-11 | — | — | EP | disclosed |
| EP-3345903-A1 | TETRACYCLIC COMPOUNDS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2018-07-11 | — | — | EP | disclosed |
| EP-2441753-B1 | TETRACYCLIC COMPOUND | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-03-30 | — | — | EP | disclosed |
| EP-2975024-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-2975024-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-9126931-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-09-08 | — | — | US | disclosed |
| US-9126931-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-09-08 | — | — | US | disclosed |
| CN-102459172-B | Tetracyclic compound | CHUGAI PHARMACEUTICAL CO LTD | 2015-06-24 | — | — | CN | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| CN-102459172-A | Tetracyclic compounds | CHUGAI PHARMACEUTICAL CO LTD | 2012-05-16 | — | — | CN | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142119-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALK 1/4885KDR 167/4885ABL1 159/4885 |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALK 1/4885KDR 167/4885ABL1 159/4885 |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALK 1/4885KDR 167/4885ABL1 159/4885 |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALK 1/4885KDR 167/4885ABL1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.